MCL1 inhibition enhances the efficacy of docetaxel against airway-derived squamous cell carcinoma cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MCL1 inhibition enhances the efficacy of docetaxel against airway-derived squamous cell carcinoma cells
Authors
Keywords
Lung, Squamous cell carcinoma, HARA, MCL1, Apoptosis, Docetaxel
Journal
EXPERIMENTAL CELL RESEARCH
Volume 406, Issue 2, Pages 112763
Publisher
Elsevier BV
Online
2021-08-04
DOI
10.1016/j.yexcr.2021.112763
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancancer survival analysis of cancer hallmark genes
- (2021) Ádám Nagy et al. Scientific Reports
- EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival
- (2020) Sachie Hirai et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling
- (2020) Sampath K. Loganathan et al. SCIENCE
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Recent advances in the development of Mcl-1 inhibitors for cancer therapy
- (2019) Alexander W. Hird et al. PHARMACOLOGY & THERAPEUTICS
- ΔNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment
- (2019) Veronica Gatti et al. Molecular Oncology
- Next-generation characterization of the Cancer Cell Line Encyclopedia
- (2019) Mahmoud Ghandi et al. NATURE
- MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells
- (2019) Makoto Tada et al. LUNG CANCER
- Elevated expression of mcl-1 inhibits apoptosis and predicts poor prognosis in patients with surgically resected non-small cell lung cancer
- (2019) Qiuyuan Wen et al. Diagnostic Pathology
- Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck
- (2019) Rachel J. Carter et al. Cell Death & Disease
- Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis
- (2018) Seiji Arai et al. CLINICAL CANCER RESEARCH
- Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition
- (2018) Clare E. Weeden et al. ONCOGENE
- Exploiting MCL-1 dependency with combination MEK + MCL-1 inhibitors leads to induction of apoptosis and tumor regression in KRAS mutant non-small cell lung cancer
- (2018) Varuna Nangia et al. Cancer Discovery
- BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
- (2018) Delphine Merino et al. CANCER CELL
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
- (2015) Takehito Shukuya et al. LANCET ONCOLOGY
- Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology
- (2011) Luisella Righi et al. CANCER
- Neisseria lactamica attenuates TLR-1/2-induced cytokine responses in nasopharyngeal epithelial cells using PPAR-γ
- (2010) L. B. Tezera et al. CELLULAR MICROBIOLOGY
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
- (2009) Adam J Bass et al. NATURE GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search